Skip to main content
HUAQING ZHIMEI has closed a Series A round for tens of millions of CNY to advance clinical bioprinting for regenerative medicine.
Funding
1 min read

HUAQING ZHIMEI has closed a Series A round for tens of millions of CNY to advance clinical bioprinting for regenerative medicine.

Huaqing Zhimei

Materials

Originally reported by 南极熊

HUAQING ZHIMEI has closed a Series A round for tens of millions of CNY to advance clinical bioprinting for regenerative medicine. This investment signals a systemic shift toward automated, patient-specific tissue engineering for wound care. By integrating 3D bioprinting with bio-inks, the company is bridging the gap between research and standardized bedside application. This move will accelerate the clinical adoption of bio-printed therapies.

Explore Huaqing ZhimeiRead Original

How This Connects

6 related events
  1. Same pattern

    CollPlant has launched BioFlex, a ready-to-print rhCollagen kit optimized for high-resolution Digital Light Processing (DLP) 3D bioprinting.

  2. Same pattern

    Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

  3. Same pattern

    PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

  4. Same pattern

    Carnegie Mellon University secured a 28.5 million dollar ARPA-H award for the LIVE project, developing 3D-printed human liver patches.

  5. Same pattern

    Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

  6. Same pattern

    Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.

  7. This article

    HUAQING ZHIMEI has closed a Series A round for tens of millions of CNY to advance clinical bioprinting for regenerative medicine.